Background: In terms of cancer mortality rates, hepatocellular carcinoma (HCC) ranks third. Direct-acting antiviral drugs (DAAs) had a profound impact on the treatment of hepatitis C virus (HCV). Objective: Understanding HCC frequency among cured HCV cases and to evaluate direct acting antiviral agents (DAAs) impact on occurrence of hepatocellular carcinoma among chronic hepatitis C patients who received these drugs. Subjects and methods: In a retrospective cross-sectional study we carried out this trial in Hepatitis Viruses' Treatment Unit, El-Ahrar Teaching Hospital, Egypt on 415 patients who received direct acting antiviral agents (DAAs) for treating chronic hepatitis C virus and achieved sustained virological response (SVR) between 2017 to 2022 where all file of cases fulfilled the inclusion as well as exclusion criteria. Result: HCC was significant in older age, male, DM, HTN and patient from rural residence. Platelet and albumin significantly decreased after HCC, but alpha fetoprotein, bilirubin, ALT, AST, serum creatinine and APRI score significantly increased after HCC. Conclusion: The incidence of HCC is highest among those who already have cirrhosis, and chronic hepatitis C is the leading risk factor of this condition. Direct anti-viral agents (DAAs) may play role in occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis C patients who achieved sustained virological response (SVR).